Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novopharm seeks ranitidine 75 mg expedited ANDA review, Torpharm petition dismissal.

This article was originally published in The Tan Sheet

Executive Summary

NOVOPHARM SEEKS EXPEDITED RANITIDINE 75 MG ANDA REVIEW by FDA in a citizen petition filed Aug. 7 in anticipation of the end of marketing exclusivity for Warner-Lambert's Zantac 75 OTC acid blocker on Dec. 19. Novopharm maintains it was the first to file an ANDA with Paragraph IV certification for generic ranitidine 75 mg. Therefore, the firm not only wants FDA's prompt consideration of its petition but also an agency dismissal of a July petition by competitor Torpharm seeking to deny Novopharm 180 days of exclusivity ("The Tan Sheet" July 27, p. 15).
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088784

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel